Non-alcoholic fatty liver disease

In the wake of the diabetes pandemic, prevalence of non-alcoholic fatty liver disease (NAFLD) is on the rise. This course sets out the health implications and potential treatments for this serious but reversible condition.

GLP-1 receptor agonists

From obscure origins in studies of lizard saliva, GLP-1 receptor agonists (GLP-1RAs) have become a staple of type 2 diabetes treatment. This course examines the ways in which they can aid type 2 diabetes management.